Racecadotril in Pediatric Acute Gastroenteritis
Racecadotril was not mentioned because current IDSA guidelines do not recommend routine use of antisecretory or antimotility agents in children with acute gastroenteritis, and the highest-quality evidence shows racecadotril provides minimal to no clinical benefit despite its theoretical safety profile in bacterial infections.
Why Racecadotril Is Not Recommended
Guideline Position on Antidiarrheal Agents
The IDSA 2017 guidelines explicitly state that antimotility agents such as loperamide should be avoided in all children < 18 years with diarrhea (strong to moderate evidence), and this caution extends to other agents that alter intestinal secretion or motility 1.
The guidelines emphasize that oral rehydration solution (ORS) is the cornerstone of treatment for mild-to-moderate dehydration, with strong evidence of efficacy, and adjunctive medications should not replace fluid therapy 1, 2.
Evidence Against Routine Racecadotril Use
The most recent 2019 Cochrane systematic review (7 RCTs, 1,140 participants) concluded that racecadotril has little benefit in improving acute diarrhea in children under five years of age and does not support routine use outside of placebo-controlled trials 3.
The Cochrane review found racecadotril may reduce rehydration failure risk (RR 0.41,95% CI 0.13 to 1.23), but the evidence was insufficient to reach definitive conclusions about duration of diarrhea or number of stools 3.
A 2017 randomized controlled trial from Kenya (120 children with severe gastroenteritis) showed racecadotril had no impact on number of stools at 48 hours, duration of hospital stay, or duration of diarrhea when added to ORS and zinc 4.
Two 2016 randomized trials from India (329 children total) demonstrated that racecadotril did not reduce diarrheal duration, stool volume, or fluid replacement requirements in children with acute gastroenteritis, including those with rotavirus infection 5.
The Safety Argument Does Not Justify Use
Why "Safe in Bacterial Infections" Is Insufficient
While racecadotril's mechanism (enkephalinase inhibition) theoretically does not affect intestinal motility and thus may not worsen bacterial clearance like loperamide does, safety alone does not justify clinical use when efficacy is not demonstrated 3, 6.
The 2019 Cochrane review found no evidence that racecadotril increased overall adverse events (RR 0.90,95% CI 0.66 to 1.22; 5 RCTs, 688 participants; low-certainty evidence), but most adverse events were mild or moderate 3.
The Kenya trial reported a 3-fold higher risk of severe adverse events in the racecadotril group (though not statistically significant, 95% CI 0.63 to 14.7), raising concerns about safety in severely ill children 4.
Clinical Practice Implications
What to Do Instead
Administer 50–100 mL of ORS after each vomiting episode as first-line therapy for mild-to-moderate dehydration (strong to moderate evidence) 1.
Continue breastfeeding throughout the illness and resume age-appropriate diet as tolerated after rehydration (strong recommendation, low-certainty evidence) 1, 2.
Reserve intravenous fluids for severe dehydration, shock, altered mental status, or ORS failure (strong recommendation, high-quality evidence) 1, 2.
Avoid all antimotility and antisecretory agents in children < 18 years unless participating in research protocols 1.
Common Pitfall to Avoid
Do not be swayed by the argument that racecadotril is "safer than loperamide" in bacterial infections—neither agent has proven clinical benefit in pediatric acute gastroenteritis, and both distract from the evidence-based cornerstone of ORS therapy 3, 4, 5.
The theoretical advantage of not affecting motility does not translate to improved patient outcomes (mortality, morbidity, or quality of life) in the highest-quality trials 3, 4, 5.